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e-mail address: salobeidan@ksu.edu.saSaleh A. Al Obeidan ⇑AbstractPurpose: Assessing the frequency and evaluating the efficacy and safety of Neodymium:Yttrium Aluminum Garnet (Nd:YAG) Laser
goniopuncture (LGP) following nonpenetrating deep sclerectomy (NPDS).
Design: Retrospective cohort study.
Patients and methods: We retrospectively reviewed the outcome of 197 eyes of 153 patients with open angle glaucoma who
underwent either NPDS or NPDS combined with cataract extraction between January 2005 and September 2010 at King Abdulaziz
University Hospital (KAUH). Both demographic and clinical data were retrieved and analysed.
Results: Goniopuncture (GP) was needed in 48 (24.4%) of the eyes which had NPDS or NPDS with cataract extraction after a mean
post operative interval of 9.78 (±11.16) months. The mean IOP had significantly decreased from 23.3 (±5.9) mmHg prior to
Nd:YAG LGP procedure to 14.6 (±4.4) mmHg at the last post-procedure assessment. At the last follow-up; Nd:YAG LGP was suc-
cessful in controlling IOP in 27 eyes (56.3%). Mean Nd:YAG LGP failure time was 6.04 (±5.80) months. Young age (<50 years)
(p = 0.001); type of glaucoma (secondary versus primary open angle, p = 0.0258) and the use of drainage implant (p = 0.038) were
the identified predicting factors for the need of Nd:YAG LGP. Complications following Nd:YAG LGP occurred in 5 eyes (iris touch
to TDM (4.2%), Hyphema (2.1%), hypotony maculopathy (2.1%) and choroidal detachment (2.1%).
Conclusions: LGP is an efficient IOP lowering procedure after NPDS, when it is indicated. It is a simple and noninvasive procedure.
However, certain precautions should be taken to avoid complications.
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Trabeculectomy is a penetrating filtration surgery widely
used for the surgical treatment of medically uncontrolled
glaucoma. The penetrating nature of this procedure may
result in several operative and postoperative complications.1
In an attempt to lower the incidence of such complications,
non-penetrating glaucoma surgery (NPGS) was developed.
This procedure is designed to avoid full thickness penetration
into the anterior chamber and consequently, minimize therisk of complications commonly encountered with the stan-
dard trabeculectomy. The NPGS was described by Krasnov
in the late 1960s.2 He suggested deroofing Schlemm’s canal
(SC) aiming to lower the intraocular pressure (IOP). However,
the effect of such procedure was relatively short, and
required a long learning curve. In addition, classic trabeculec-
tomy was introduced in the same era and it was easier to
perform, had higher efficacy and longer longevity. As a
result, the popularity of NPGS was quite limited. In thee:
al.com
Figure 1. Gonioscopic view of the trabeculo-Descemet’s membrane with
clear deposition of pigments and debris indicating the area of filtration.
96 S.A. Al Obeidan1980s, NPGS started to gain popularity again, and different
techniques with several modifications were described.3–10
Nonpenetrating deep sclerectomy (NPDS) is one of the
NPGS procedures, commonly used for surgical management
of open angle glaucoma. In NPDS, removal of a deep scleral
flap leads to the formation of an empty scleral space known
as ‘the decompression space’, where the aqueous humour
gets collected before its drainage.11 The literature reports
that the aqueous outflow resistance is mainly located in the
Trabecular Meshwork (TM), with approximately 75% of this
resistance both in normal and abnormal glaucomatous eyes
occurring in the juxtacanalicular TM and the inner wall of
SC.12 Therefore, NPDS was developed to address this
resistance through deroofing SC and peeling its floor,
together with the juxtacanalicular TM and part of the
corneoscleral layers of TM. As a consequence, aqueous
drainage occurs at the level of the posterior trabeculum
through the remaining corneoscleral TM and the intact uveal
part of the TM (Trabeculo-Descemet’s Membrane,
TDM).3,13,14 Physiologically, the TDM acts as an outflow
resistance site, allowing gradual decrease of IOP which in
turn precludes the sudden hypotony that usually occurs after
trabeculectomy.15,16 Several routes have been suggested for
the aqueous drainage from the decompression space. One of
the potential routes is the subconjunctival space as demon-
strated by the presence of a filtering bleb in the majority of
successful cases.13,17 Other suggested routes are drainage
through the suprachoroidal space and through a transcleral
pathway. Furthermore, aqueous may enter the SC to be
drained by the episcleral venous plexus.13 To facilitate IOP
lowering efficacy, space-maintaining devices in NPDS were
introduced. These devices are used to reduce scar formation
and to keep the decompression space open during the time
of maximal healing, which consequently enhances the drain-
age process. Nowadays, different absorbable and nonab-
sorbable; expensive and low cost; animal-, chemical-based
and synthetic space-maintaining devices are being used.13
Examples of the commonly used devices are: collagen
implants (STAAR Surgical Company, California, USA),
reticulated hyaluronic acid implant (SKGel™, Corneal Labora-
tories, Paris, France), nonabsorbable hydrophilic acrylic
implant (T-flux, loltech, La Rochelle, France), and viscoelas-
tic implant (e.g. Healaflow, Anteis S.A., Geneva, Switzerland).
In some patients, the TDM may demonstrate an increased
resistance to aqueous outflow either in the early or late post
operative period causing elevation of IOP.14 The insufficient
passage of aqueous humour through the TDM is usually
due to fibrosis developed as a part of the TDM healing
process or due to excessive deposition of debris and or pig-
ments (Fig. 1). Goniopuncture is effective when underfiltra-
tion is due to poor TDM functionality and not due to other
causes such as poor dissection plane, excessive bleb fibrosis
or other more serious causes.13 Additionally, it is considered
as a minor follow up procedure equivalent to postoperative
scleral flap suture lysis after trabeculectomy.
Laser goniopuncture (LGP) converts deep sclerectomy
from being a nonpenetrating procedure to a penetrating
one, but with fewer complications compared to penetrating
glaucoma surgery.
In the present study, we assessed the frequency, efficacy
and safety of Nd:YAG LGP following NPDS performed at
glaucoma service unit, King Abdul-Aziz University Hospital(KAUH), King Saud University, Riyadh, Kingdom of Saudi
Arabia.Materials and methods
In the current retrospective cohort study, 153 charts of
patients who underwent a NPDS or NPDS with cataract
extraction for medically uncontrolled primary or secondary
open-angle glaucoma between January 2005 and September
2010 were reviewed. Our exclusion criteria included
congenital glaucoma cases. However, cases with previous
ocular surgery such as filtering procedure or cataract
extraction were not excluded. Indications for surgery were
uncontrolled glaucoma, which was defined as an intraocular
pressure (>21 mmHg) with maximum tolerated anti-glau-
coma medication, progressive glaucomatous visual field loss
and/or progressive optic disk cupping. Mitomycin C was
used in all the cases. Steps of our NPDS technique were as
follows: after a fixation suture (a 4–0 silk suture to the supe-
rior rectus muscle or a 6–0 vicryl suture to the superior cor-
nea) had been placed, a fornix-based conjunctival flap was
fashioned, and a 5  5 mm one-third sclera thickness superfi-
cial flap was created, which extended 1.5 mm into the clear
cornea. A sponge soaked in Mitomycin C solution 0.2 mg/
ml was placed under the superficial scleral flap and Tenon’s
capsule for 2 min, then thorough irrigation with 20 cm3 bal-
anced salt solution was performed to wash the surgical site.
A 4  4 deep scleral flap was created leaving only a very thin
layer (50–70 lm) of scleral tissue over the uvea. Dissection
was carried out from the posterior part of the flap and
extended anteriorly to deroof SC spontaneously. Dissection
continued anteriorly to create the TDM. The floor of SC
was peeled off with fine-toothed forceps (Fig. 2) and the
deep flap was excised.
If an implant was used, it was then placed in the floor of
the excised deep flap (Fig. 3). The superficial scleral flap
was then secured with 10–0 nylon sutures at the posterior
corners. The conjunctival flap was closed in a watertight fash-
ion. An Implant drainage device, such as T-flux (loltech, La
Rochelle, France), SKGel™ (Corneal Laboratories, Paris,
France) or Healaflow was used in the majority of cases. Post
operatively, all patients received topical steroid in a tapering
dose and topical antibiotic eye drop.
Figure 2. Peeling of the floor of the Schlemm’s canal with fine-toothed
forceps.
Figure 3. SK-GEL™ placed in the floor of the deep flap.
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patient was not achieved because of insufficient filtration
through the TDM. For example in our glaucoma division,
the target IOP at which LGP was performed depends on
the type of glaucoma as well as the status of optic nerve
head. The target IOP for normal tension glaucoma and those
patients with advanced glaucomatous disk damage (C/
DP 0.8) is <15 mmHg. In patients with less severe glauco-
matous, disk damage, the target IOP is <21 mmHg. It was
performed using the gonioscopy contact lens. The laser
aiming beam was precisely aimed just anterior to the slightly
pigmented part of the TDM to avoid a prolapse of the
iris into the goniopuncture site. Using the free-running
Q-switched mode with energy adjusted to 3–4 mJ, a few
shots were usually enough to induce microperforation in
the TDM. Following the procedure; topical 1% prednisolone
acetate eye drops were prescribed for few days (3 days toone week) to quiet the eye. However, more frequent and
longer duration of treatment with prednisolone acetate eye
drops was used in uveitic glaucoma cases.
For each patient, the following data were collected: age;
gender; type of open-angle glaucoma; the eye to undergo
surgery; preoperative visual acuity and IOP; number of pre-
operative antiglaucoma medications; optic nerve cup-to-disk
ratio; previous ocular surgeries (if any); type of implant
drainage device used; intraoperative and postoperative
complications. Additionally, duration of the post operative
follow-up; visual acuity; IOP and number of anti-glaucoma
medications used at the last follow-up visit were recorded.
If LGP was performed; the following data were noted: the
interval between NPDS and LGP, preLGP IOP, and
(1–2 weeks) postLGP IOP as well as at the subsequent
follow-up visits which varied depending on the IOP level,
and at the last visit. Complications following LGP were
recorded. If the IOP failed to drop to target levels, glaucoma
medications were added and the time of medication addition
was obtained. In addition, the need for any further surgical
interventions; including filtering procedures after Nd:YAG
LGP, was noted.Statistical methods
Data were collected in a questionnaire form. All records
with missing data, inconvenient conflictions and/or outlier
results were removed. Data were then entered into a specif-
ically designed database using Microsoft Access 2007
where necessary data management was done. Data analysis
was conducted using SPSS version 19.0 (IBM Inc., Chicago,
Illinois), MedCalc 11.6 (MedCalc Software bvba,
Mariakerke, Belgium) and StatsDirect statistical software,
version 2.7.2 (StatsDirect Ltd., Cheshire, UK).
Descriptive statistics were calculated to both numerical
and categorical data. Inferential analysis was conducted to
compare means for pre and post intervention indices using
Student’s paired T test, while Chi2 was conducted to investi-
gate the association between other variables. P-value < 0.05
was considered significant. Survival analysis using Kaplan
Meier survival curve was done to estimate the mean and
median survival function of cases post operatively.
Definition of success: In this study, complete success was
defined as: achieving a post intervention IOP <21 mmHg
based on the patient’s pre-intervention status without any
anti-glaucoma medication. Qualified success was defined
as: achieving a post intervention IOP <21 mmHg with the
help of anti-glaucoma medication. Cases which developed
uncontrolled IOP >21 mmHg with medication and/or were
in the need for further surgical interventions were considered
as ‘‘failed’’.Results
In the current study, NPDS was performed to 213 eyes of
158 patients with or without cataract extraction from January
2005 to September 2010 at the King Abdul Aziz University
Hospital (KAUH). After data management, 6 eyes of 5
patients were excluded from this cohort and the analysis
was eventually performed to 197 eyes of 153 patients.
Patients were in the mean age of 44.9 (±20.2) years, and an
equivalent male to female ratio (76; 49.7% to 77; 50.3%
98 S.A. Al Obeidanrespectively). The majority of cases were unilateral (109;
71.2%) presenting with moderate mean (±SD) level of IOP
(25.5 (±10.2)) mmHg under a mean number of antiglaucoma
medications (2.9 (±0.9)) and within a mean cup to disk
ratio of 0.8 (±0.2). Previous ocular surgeries were done to
13; 6.6%. Combined NPDS/phacoemulsification procedures
were done to 34 (17.3%) of them, while, the most prevalently
used implant was SK-Gel in 59 (29.9%) eyes and the operated
eyes were followed up to a mean (±SD) follow up duration of
25.4 (±22.3) months. Details on demographic and clinical
indices at presentation are demonstrated in Table 1.
Out of the 197 eyes, nearly one-forth (48 eyes; 24.4%) of
43 patients needed LGP. Within this specific group of
patients, the mean (±SD) age was 34.9 (±18.4) years, mean
preoperative IOP was 28.8 (±12.3) mmHg, CDR: 0.7 (±0.3)
and anti-glaucoma medications: 3.3 (±0.8). The majority of
such glaucoma cases were diagnosed as: uveitic OAG (21;
43.8%) followed by primary OAG (15; 31.3%), juvenile (5;
10.2%), Pseudo-exfoliation (2; 4.2%), Steroid induced (2;
4.2%), in addition to a single case (2.1%) of each of the fol-
lowing diagnoses; angle recession, normal tension and com-
bined mechanism glaucoma. Previous ocular surgeries were
done in 6 (12.5%) cases. The majority of surgeries were done
with SK-Gel implant (18; 37.5%), while combined NPDS/
phaco procedure was done in 2 (4.2%) eyes). LGP was per-
formed as the initiative procedure if the target IOP was not
achieved after excluding adherence of the iris to the TDMW.
The mean duration between conduct of NPDS and the need
for Nd:YAG LGP was 9.78 (± 11.16) months while these cases
were followed up for mean follow-up of 16.7 (±16) ranging
from 3 to 48 months after the LGP. Prior to LGP, the Mean
IOP was 23.3 (±5.9) mmHg which significantly decreased to
14.6 (±4.4) mmHg at the last follow-up after the procedure
(p < 0.001), and, the mean number of anti-glaucoma medica-
tions has significantly decreased from a pre LGP value of 3.3
(±0.8) to post LGP value of 0.54 (±0.9); p < 0.001.
At the last follow up visit, Nd:YAG LGP was successful in
controlling the IOP in 27 eyes (56.3%); whereas 21 eyes
(43.7%) needed further management to lower IOP; 11
(22.9%) were conveniently managed by anti-glaucoma
medications, and 10 (20.8%) required surgical interventions.Table 1. Sample distributed by demographic and clinical data at presentation.
Characteristic/indicator Category
Age (years)
Gender
Male
Female
Laterality
Unilateral
Bilateral
Type of surgery (eyes)
NPDS (only)
Combined NPD
Type of implant
None
Healaflow
SK-Gel
T-Flux
Preoperative IOP
Preoperative anti-glaucoma medications
Preoperative CDR
History of previous ocular surgery
NPDS: Non Penetrating Deep Sclerectomy, Phaco: Phacoemulsification, SD: Standard Devi
Sclerectomy; Phaco: Phacoemulsification; IOP: Intra-ocular pressure; CDR: Cup/Disk ratio.In our sample, 10 eyes of 8 patients (2 bilateral) were diag-
nosed as normal tension glaucoma with a pre intervention
IOP of 16.4 (2.5) on anti-glaucoma medications. The mean
post-intervention IOP of those patients was significantly
reduced to 12.5 (2.6), and they were categorized as a
complete success. Only one case (unilateral, male, age
32 years) needed Goniopuncture after 3 months of follow
up, where the IOP raised to 20 mmHg on one medication.
In the post LGP assessment, the patient’s eye was quiet
and stable with a final IOP of 15 mmHg (CDR: 0.6; VA: 20/20).
Moreover, Kaplan Meier Survival analysis yielded that: the
estimated mean survival time after Nd:YAG LGP is
35.6 (±4.1) months (95% CI: 27.755–43.479), median survival
time is: Median 43.48 (10.27) (22.870–63.130) (Fig. 4). Post
Nd: YAG LGP intervention, 5 (10.5%) eyes developed compli-
cations where, iris to TDM was detected in 2 (4.2%) cases,
and hyphema, hypotony maculopathy, choroidal detachment
in one (2.1%) case each.
Conduct of univariate analysis to assess potential risk fac-
tors for the subsequent need of post NPDS Nd: YAG LGP
showed that: three predicting factors were found to be statis-
tically significant, those are; age (<50 years, p = 0.001); type
of glaucoma (secondary, p = 0.026), and the use of drainage
implants (p = 0.038). Further in-depth analysis to different
types of secondary open angle glaucoma, uveitic open angle
glaucoma was the type significantly associated with the later
need of Nd:YAG LGP (p = 0.0003) (Table 2).Discussion
Nonpenetrating glaucoma surgery (NPGS) has been
recently modified to improve the safety of filtering proce-
dures through avoiding full thickness penetration into the
anterior chamber. The goal of different NPGS procedures is
to reduce IOP by overcoming the outflow resistance which
is mainly attributed to the inner wall of Schlemm’s canal and
the adjacent trabeculum.18 In NPDS, a physiologic membrane
consisting of the rest of trabecular tissue and the Descemet’s
membrane, this membrane is called the Trabeculo-
Descemet’s Membrane (TDM). It dramatically increasesNo. (%) Mean (±SD)
44.9 (20.2)
76 (49.7)
77 (50.3)
109 (71.2)
44 (28.8)
163 (82.7)
S/Phaco 34 (17.3)
31 (15.7%)
52 (26.5%)
59 (29.9%)
55 (27.9%)
25.5 (10.2)
2.9 (0.9)
0.8 (0.2)
13 (6.6%)
ation, IOP: Intraocular Pressure SD: Standard deviation; NPDS: Non penetrating deep
Table 2. Predicting factors for the need of Nd:YAG LGP.
Characteristic Category Nd:YAG LGP Total P value
No. (%)
Age
<50 36 (33.3%) 108 0.001*
P50 12 (13.5%) 89
Pre op. IOP
<21 17 (20.7%) 82 0.316
P21 31 (27.0%) 115
No. of pre Op. medications
<2 2 (12.5%) 16 0.366
P2 46 (25.6%) 180
Type of glaucoma
Primary 15 (16.9%) 89
Secondary 33 (30.6%) 108 0.026*
Early post op. hypotony (<6)
Yes 1 (20.0%) 5 0.890
No 47 (24.5%) 192
NPDS combined with phaco.
Yes 2 (5.9%) 34
No 46 (28.2%) 163 0.006*
Use of implant
Yes 45 (27.1%) 166 0.038*
No 3 (9.7%) 31
Nd:YAG LGP: Neodymium: Yttrium Aluminum Garnet Laser goniopuncture; Pre Op.:
Preoperative; IOP: Intraocular Pressure; Post Op.: Postoperative; NPDS: Non Pene-
trating Deep Sclerectomy; Phaco: Phacoemulsification.
* Statistically significant at p < 0.05, 95% confidence interval.
Figure 4. Probability of Nd:YAG LGP success.
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vent the sudden globe decompression that commonly occurs
after penetrating glaucoma surgeries.19
When the filtration through the membrane is considered
to be insufficient resulting in elevation of IOP, a goniopunc-
ture intervention can be performed with Nd:YAG laser to
create a hole in the TDM. This transforms a nonpenetrating
filtering procedure into a penetrating one. Nevertheless,
such transformation does not compromise on the high safety
profile of NPDS afforded by the lack of intraoperative
penetration.
In the current study, LGP was performed in 24.4% of eyes
that either had NPDS or NPDS with cataract extraction. The
mean (±SD) IOP prior to Nd:YAG LGP was 23.3 (±5.9) mmHg
which decreased to 14.6 (±4.4) mmHg at the post procedure
last follow-up assessment. The mean interval betweensurgery and LGP was 9.78 (±11.16) months while the
mean follow up after LGP was 16.7 (±16) months. Mermoud
et al. performed LGP in 41% of total number of studied
patients.14 The mean time duration between surgery and
LGP was 9.9 (±1.2) months. Moreover, the mean IOP was
reduced from a pre LGP value of 22.2 (±7.0) mmHg to
12.5 (±5.8) mmHg after laser intervention. More recently,
Anand and Pilling reported a success rate of LGP of
67.0%,20 in their study, the IOP was reduced from
19.6 (±4.6) mmHg to 14.3 (±6.7) mmHg after two years
follow up. A meticulous review of the literature shows a lot
of variation in the reported rates of LGP ranging from 4.6%
to 81%. Findings from these different studies are briefed in
Table 3.
In a critical evaluation study of nonpenetrating glaucoma
surgery21, Sarodia et al. reported that success rates of NPDS
seem to be lower when LGP rate is low. Consequently, the
frequency of LGP increased as there is an increasing evidence
on its IOP lowering effect.
In the current study, 24.4% of our cases needed LGP after
a mean follow up of 25.03 (±22.03) months, with a success
rate of 56.3%. It has been noticed that the need for LGP
increases with longer follow up after deep sclerectomy to
achieve a within target IOP range.20 Montanes et al. showed
that LGP rate increased from 17.6% during the first year to
69.6% with a follow up longer than 2 years.22
This study has identified four predicting factors for the
subsequent need of LGP. One of the factors was being at
younger age (<50 years). Younger individuals have a stronger
healing process which may lead to earlier fibrosis of the TDM
and consequently, the later need of LGP.23 In contrast to our
finding, Mermoud et al.14 did not find patients’ age as a risk
for the need of Nd:YAG LGP. Meanwhile, among our series,
the mean age (34.88 ± 18.35 years) was younger than their
mean age (67.8 ± 12.7 years). Furthermore, none of their
patients were diagnosed to have uveitic open angle
glaucoma.
Another risk factor was the diagnosis of secondary open
angle glaucoma (p = 0.026); of which, specifically, uveitic
open angle glaucoma was significantly associated with the
need of Nd:YAG LGP (p = 0.0003). Mermoud et al.14 showed
a tendency for an increased need for goniopuncture in
patient with pseudoexfoliative and primary open angle
glaucomas in pseudophakia. Ollikainen et al.24 showed that
Nd:YAG LGP was performed more often postoperatively in
pseudoexfoliation eyes than in their primary open angle
glaucoma counterparts (p = 0.047).
In our study, the third predicting factor was the use of
drainage implants (p = 0.038). In a study by Devloo et al.25,
reported that Nd:YAG LGP was performed more frequently
and earlier in patients who had NPDS with autologous scleral
implant than those who had NPDS only (50% and 30%,
respectively). However, the difference was not statistically
significant. They attributed this finding to a possible
implant-induced fibrosis. Additionally, Sanchez et al.5 found
an equal rate of Nd:YAG LGP in patients who had NPDS
alone and those who had NPDS with collagen device
(15% in each group). Similar findings were reported by
Al-Shaarawy and Mermoud.26 Lachkar et al.27 reported a
Nd:YAG LGP rate of 47.3% in patients who underwent NPDS
with collagen device, and 46.9% in patients who had NPDS
with 5-FU. A relatively recent meta-analysis by Hondur et al.28
Table 3. Laser goniopuncture rates for deep sclerectomy.
Author Procedure n Mean LGP rate (%) Mean LGP
timing (months)
Mean preLGP
IOP (mmHg)
Mean postLGP
IOP (mmHg)
Reduction
in IOP
Khairy et al.18 DS 43 4.6 NA NA NA NA
El Sayyad et al.32 DS 39 10.3 9.6 NA NA 7.4 mmHg
Shaarawy33 DS 52 40 23.7 23.6 16.7 29%
Wishart et al.34 DS 52 19 20.6 33.5 20.6 38.5%
Devloo et al.25 DS 69 30 NA 23.75 16 29.42%
Shaarawy & Mermoud26 DS 26 46 13.2 19.5 14.7 NA
Mousa11 DS + implant 20 45 NA NA NA NA
Bissig et al.15 DS + implant 105 59.8 29 19.8 12 39.4%
Mermoud et al.14 DS + implant 100 41 9.9 22.2 12.5 NA
Shaarawy19 DS + implant 105 51 21 20 11 45%
Jehn et al.35 DS + implant 27 30 NA NA NA NA
Devloo et al.25 DS + implant 24 50 NA 25.63 15.75 37.03%
Shaarawy & Mermoud26 DS + implant 26 46 14.5 22 7.3 NA
Ates et al.36 DS + implant 54 5.5 NA NA NA NA
Drolsum37 DS + implant 29 44.8 NA NA NA NA
Ravinet et al.38 DS + implant 22 50 10 NA NA 5.1 mmHg
Hamel et al.39 DS + implant 21 71.4 NA 20.3 11.5 43.3%
Lachkar et al.27 DS + implant 157 47.3 NA NA NA NA
Ates et al.40 DS + implant 23 13 NA NA NA NA
Mermoud et al.41 DS + implant 44 23 9.1 21.0 12.0 NA
Wevill et al.42 DS + implant 17 22 1 NA NA NA
Anand and Atherley43 DS + implant 19 81 NA NA NA NA
Anand and Pilling20 DS + implant ± MMC 258 67 10.3 19.6 14.3 NA
Ollikainen et al.24 DS + implant + MMC 31a 29 NA 24.4 12.9 NA
Ollikainen et al.24 DS + implant + MMC 37b 55.6 NA 26.2 10.6
Anand & Atherley43 DS + implant + MMC 52 45 NA NA NA NA
Mendrinos et al.44 DS + implant ± MMC 22 63.6 16.6 21.8 9 NA
Lachkar et al.27 DS + 5-FU 90 46.9 NA NA NA NA
n: number of eyes in the study; LGP: Laser goniopuncture; IOP: Intraocular pressure; DS: Deep Sclerectomy; MMC: Mitomycin C.
a Eyes with primary open angle glaucoma.
b Eyes with pseudoexfoliative glaucoma.
100 S.A. Al Obeidanshowed that the rate of Nd:YAG LGP after NPDS ranged
between 4.6% and 40%; while after NPDS with implant, it
ranged between 5.5% and 81%. Fourth, of the 34 patients
who had NPDS with cataract extraction in our series, only 2
patients (5.9%) needed Nd:YAG LGP later, whereas Nd:YAG
LGP was performed in 28.2% of those who had NPDS alone.
The difference was statistically significant (p = 0.006). This
finding may imply that combining cataract extraction with
NPDS is a ‘protective’ factor against the subsequent need
of Nd:YAG LGP. It was reported earlier that cataract
extraction without filtering surgery may result in a small but
significant decrease of IOP in glaucoma patients, glaucoma
suspects, and normal patients.28
Several mechanisms for the reduction of IOP after phacoe-
mulsification have been proposed. The anterior chamber is vis-
ibly deeper in a unilateral pseudophakic eye compared with
the fellow phakic eye. This postoperative increase in angle
width with its potential effect on the trabecular meshwork
may lead to increased aqueous outflow and consequently to
IOP reduction. Another possible mechanism for IOP reduction
may be traction on the ciliary body via the zonules in the pres-
ence of a contracting capsule. Such traction could possibly
lead to decreased aqueous secretion and hence, lower IOP.
The increase in prostaglandin F2 levels postoperatively may
increase uveoscleral outflow and again lower IOP.28 Another
possible mechanism of less need for LGP after combined
DS + Phaco + MC IOL is possibility of spontaneous rupture
of TDW during irrigation aspiration of viscolelastic material
at the end of procedure where most surgeons follow.
D’Eliseo et al.29 compared NPDS with implant and com-
bined glaucoma surgery (NPDS and phacoemulsification).
They reported that: as the angle widens with lens extraction,phacoemulsification seems to lower the risk of iris adherence
at the TDM, thus decreasing the risk of internal filtration
block in patients who had NPDS with phacoemulsification.
The most common complication following LGP in the cur-
rent study was iris touch or adherence to the TDM in two eyes
(4.2%). In one eye it resulted in a rise of IOP, necessitating the
need for Nd:YAG laser treatment to release the touch. The
TDM remained free of any recurrent touch throughout the
follow up period and IOP was within the target range. A sim-
ilar complication was reported by Kim et al.30
Iris adherence to the TDM can occur without a previous
Nd:YAG LGP (Fig. 5). Other common iris-related complica-
tions after LGP are iris incarceration and iris prolapse in the
Trabeculo–Descemet’s Window created by the LGP20,24,25,31
Vuori reported a spontaneous iris prolapse after LGP in three
patients out of 31 patients who underwent LGP. In two
patients, the decrease in IOP following LGP was substantial,
which may have contributed to the prolapse.31 A recent study
showed a 2.0% incidence of iris prolapse.24 Iris incarceration
can be easily overlooked because it is not necessarily accom-
panied by pupil deformation.25 Therefore, it is advised to do
regular gonioscopy at each follow up visit to check for iris
synechiae and incarceration.
Other reported complications following LGP may include:
Hyphema,20 choroidal detachment,14,20,24 hypotony, hypot-
ony maculopathy, blebitis and delayed bleb leak.20 In the
present study, choroidal detachment occurred in one eye
(2.1%) and hypotony maculopathy in another eye (2.1%). In
both cases, LGP was performed few days after NPDS and
the drop in IOP was substantial. Similarly, Mermoud et al.,14
reported 2 cases of choroidal detachment. All of the cases
had a substantial drop in IOP following LGP.
Figure 5. Iris adherence to most of trabeculo-Descemet’s membranes
(arrow), discovered on routine gonioscopic examination. No previous
goniopuncture had been performed, and intraocular pressure was well
controlled without medications.
Nd: YAG laser goniopuncture following nonpenetrating deep sclerectomy 101Those findings highlight the fact that avoiding early LGP
and lowering highly elevated IOP with medications prior to
the procedure should be considered before deciding on
performing LGP.
In conclusion, NPDS is a safe filtering procedure; however,
insufficient filtration through TDM may occur with time.
Nd:YAG LGP creates an opening in the TDM; which enables
aqueous humour filtration from the anterior chamber to the
scleral decompression space. It is a simple, effective and non-
invasive procedure, equivalent to postoperative scleral flap
suture lysis after trabeculectomy. However, it is not a compli-
cation-free procedure.Conflict of interest
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